Skip to main content
Publications
Yih WK, Kulldorff M, Sandhu SK, Zichittella L, Maro JC, Cole DV, Jin R, Kawai AT, Baker MA, Liu C, McMahill-Walraven CN, Selvan MS, Platt R, Nguyen MD, Lee GM. Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System. Pharmacoepidemiol Drug Saf. 2016 May;25(5):481-92. doi: 10.1002/pds.3908
Kawai AT, Li L, Kulldorff M, Vellozzi C, Weintraub E, Baxter R, Belongia EA, Daley MF, Jacobsen SJ, Naleway A, Nordin JD, Lee GM. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf. 2014 May;23(5):548-53. doi: 10.1002/pds.3575
Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S. Safety of mf59-adjuvanted influenza vaccination in the elderly: results of a comparative study of mf59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. Am J Epidemiol. 2013 Oct;178(7):1139-45.
Papanicolaou S, Kontodimas S, Syriopoulou E, Tsolia M, Theodoridou M, Kremastinou J, Tzanakaki G, Strutton D, Hwang S, Earnshaw SR. Clinical and economic benefits of national immunization with the 13-valent compared to 7- and 10-valent pneumococcal conjugate vaccines in Greece. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A423-4.